Company Research Report: Pacira BioSciences, Inc.

---

Company Overview

• Name: Pacira BioSciences, Inc.

• Mission: Providing non-opioid pain management and regenerative health solutions aimed at improving patient outcomes.

• Founded: No information is available.

• Founders: No information is available.

• Key People:

• Frank D. Lee, Chief Executive Officer and Director

• Daryl Gaugler, Chief Operating Officer

• Kristen Williams, JD, Chief Administrative Officer and Secretary

• Jonathan Slonin, MD, Chief Medical Officer

• Shawn Cross, Chief Financial Officer

• Christopher Young, Chief Manufacturing Officer

• Anthony Molloy III, Esq., Chief Legal and Compliance Officer

• Headquarters: No information is available.

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known for: Leading provider of non-opioid pain management and regenerative health solutions. The company focuses on advancing patient care through opioid-reducing strategies.

Products

EXPAREL® (Bupivacaine Liposome Injectable Suspension)

• Description: A local anesthetic used at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain.

• Key Features:

• Provides pain control by turning off the body’s pain signals when injected into the surgical site.

• Approved for patients aged 6 years and older for postsurgical local analgesia and adults for certain nerve blocks.

• Utilized in various surgical procedures across multiple specialties, including general, oral, orthopedic, pediatric, and women’s health.

iovera°

• Description: An FDA-approved non-opioid treatment that alleviates pain through cryoanalgesia, applying cold therapy to a specific nerve to interrupt pain signal transmission.

• Key Features:

• Provides immediate pain relief, lasting up to three months as the nerve regenerates.

• Can significantly reduce opioid prescriptions post-surgery.

• Indicated for pain associated with orthopedic surgery and conditions like osteoarthritis of the knee.

ZILRETTA® (Triamcinolone Acetonide Extended-Release Injectable Suspension)

• Description: A non-opioid treatment option utilizing extended-release microsphere technology for osteoarthritis knee pain.

• Key Features:

• Provides significant extended relief from knee pain.

• Demonstrates significant improvement in pain intensity scores over saline control in trials.

• Microspheres localize in synovial tissue, a primary source of knee pain.

Recent Developments

• Recent Developments: No specific recent developments listed.

• New Product Launches: No new product launches were specifically mentioned.

• New Features: No new features added to existing products were specified.

• Partnerships: The company is actively building a coalition of organizations to advocate for non-opioid pain management solutions.

This professional report highlights Pacira BioSciences' commitment to reducing reliance on opioid medications by offering innovative, non-opioid pain management solutions, as reflected in their core values and product offerings. This analysis draws on the data available to present a detailed and concise overview suitable for stakeholders and analysts interested in the market dynamics surrounding pain management and pharmaceutical advancements.